Cocrystal Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Cocrystal Pharma ha aumentado sus beneficios a una tasa media anual de 18.2%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento anual de 1.2%. Los ingresos han ido disminuyendo a una tasa media de 84% al año.

Información clave

18.2%

Tasa de crecimiento de los beneficios

50.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	-84.0%
Rentabilidad financiera	-147.2%
Margen neto	n/a
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Oct 18

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13

Desglose de ingresos y gastos

Cómo gana y gasta dinero Cocrystal Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:COCP Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	0	-19	6	0
30 Jun 24	0	-18	6	0
31 Mar 24	0	-17	6	0
31 Dec 23	0	-18	6	0
30 Sep 23	0	-18	6	0
30 Jun 23	0	-20	6	0
31 Mar 23	0	-40	6	0
31 Dec 22	0	-39	6	0
30 Sep 22	0	-38	5	0
30 Jun 22	0	-36	6	0
31 Mar 22	0	-16	6	0
31 Dec 21	0	-14	5	0
30 Sep 21	1	-12	6	0
30 Jun 21	1	-11	5	0
31 Mar 21	2	-10	6	0
31 Dec 20	2	-10	6	0
30 Sep 20	2	-56	6	0
30 Jun 20	2	-55	6	0
31 Mar 20	2	-53	5	0
31 Dec 19	7	-48	5	0
30 Sep 19	6	-45	5	0
30 Jun 19	6	-45	5	0
31 Mar 19	5	-45	4	0
31 Dec 18	0	-49	4	0
30 Sep 18	0	0	4	0
30 Jun 18	0	0	4	0
31 Mar 18	0	0	3	0
31 Dec 17	0	-1	3	0
30 Sep 17	0	-72	3	0
30 Jun 17	0	-71	2	0
31 Mar 17	0	-73	3	0
31 Dec 16	0	-75	4	0
30 Sep 16	0	-40	6	0
30 Jun 16	0	-38	8	0
31 Mar 16	0	-38	8	0
31 Dec 15	0	-50	7	0
30 Sep 15	0	-22	4	0
30 Jun 15	0	-24	3	0
31 Mar 15	0	-16	2	0
31 Dec 14	0	0	2	0
30 Sep 14	0	1	1	-3
30 Jun 14	0	3	1	-2
31 Mar 14	0	-3	1	-1

Ingresos de calidad: COCP actualmente no es rentable.

Margen de beneficios creciente: COCP actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: COCP no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 18.2% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de COCP en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: COCP no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (54.6%).

Rentabilidad financiera

Alta ROE: COCP tiene una rentabilidad financiera negativa (-147.23%), ya que actualmente no es rentable.

Cocrystal Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Third quarter 2020 earnings released: US$0.046 loss per share

Recent updates

New major risk - Financial position

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Price target decreased by 11% to US$8.00

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Cocrystal Pharma updates on COVID-19 antiviral development programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Cocrystal sees 2021 cash burn of $800k a month

Cocrystal Pharma to test CDI-45205 against coronaviruses

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71

Third quarter 2020 earnings released: US$0.046 loss per share

New 90-day low: US$0.84

Cocrystal Pharma, Inc. Provides Update on Influenza A Program

United States District Court for the District of New Jersey Enters an Order Preliminarily Approving the Stipulation and Agreement of Settlement with Cocrystal Pharma, Inc

New 90-day low - US$0.93

Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $15.000001 million.

New 90-day high - US$2.36

Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Value Index

Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Index

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica